$ONMD
OneMedNet Corp Stock $onmd

$onmd Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224049637 Filed on December 11, 2024

Income Statement

Concept	2024 Q2	2023 Q2
Revenue	$227.0K	$0.00
YoY Change
Cost Of Revenue	$329.0K	$230.0K
YoY Change	43.04%
Gross Profit	-$102.0K	-$57.00K
YoY Change	78.95%
Gross Profit Margin	-44.93%
Selling, General & Admin	$1.969M	$40.00K
YoY Change	4822.5%	-20.0%
% of Gross Profit
Research & Development	$383.0K	$579.0K
YoY Change	-33.85%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.352M	$290.0K
YoY Change	711.03%	-63.5%
Operating Profit	-$2.454M	-$285.5K
YoY Change	759.68%	-64.07%
Interest Expense	$15.00K	$340.0K
YoY Change	-95.59%	127.65%
% of Operating Profit
Other Income/Expense, Net	-$1.135M	$0.00
YoY Change
Pretax Income		$57.55K
YoY Change		-93.94%
Income Tax		$62.71K
% Of Pretax Income		108.96%
Net Earnings	-$3.600M	-$5.158K
YoY Change	69694.49%	-100.54%
Net Earnings / Revenue	-1585.9%
Basic Earnings Per Share	-$0.15	-$2.38
Diluted Earnings Per Share	-$0.15	$0.00
COMMON SHARES
Basic Shares Outstanding	23.85M shares	4.033M shares
Diluted Shares Outstanding	23.94M shares	4.033M shares

Balance Sheet

Concept	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$0.00
YoY Change		-100.0%
Cash & Equivalents	$407.0K	$3.438K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$75.00K
Other Receivables
Total Short-Term Assets	$956.0K	$3.438K
YoY Change	27706.86%	-54.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$85.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$30.00M
YoY Change		-74.72%
Other Assets
YoY Change
Total Long-Term Assets	$85.00K	$29.98M
YoY Change	-99.72%	-74.74%
TOTAL ASSETS
Total Short-Term Assets	$956.0K	$3.438K
Total Long-Term Assets	$85.00K	$29.98M
Total Assets	$1.041M	$29.98M
YoY Change	-96.53%	-74.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses		$2.000M
YoY Change		87.63%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.05M	$2.091M
YoY Change	858.77%	79.32%
LONG-TERM LIABILITIES
Long-Term Debt		$3.700M
YoY Change		221.74%
Other Long-Term Liabilities	$22.00K	$3.283M
YoY Change	-99.33%	-27.34%
Total Long-Term Liabilities	$22.00K	$3.283M
YoY Change	-99.33%	-42.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.05M	$2.091M
Total Long-Term Liabilities	$22.00K	$3.283M
Total Liabilities	$20.23M	$10.13M
YoY Change	99.69%	48.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$97.10M	-$11.72M
YoY Change	728.22%	77.25%
Common Stock	$2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$19.19M	-$10.09M
YoY Change
Total Liabilities & Shareholders Equity	$1.041M	$29.98M
YoY Change	-96.53%	-74.74%

Cashflow Statement

Concept	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$3.600M	-$5.158K
YoY Change	69694.49%	-100.54%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$600.0K
YoY Change		295.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$90.00K
YoY Change		-107.83%
Cash From Investing Activities		$90.00K
YoY Change		-107.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		500.0K
YoY Change		-56.52%
NET CHANGE
Cash From Operating Activities		-600.0K
Cash From Investing Activities		90.00K
Cash From Financing Activities		500.0K
Net Change In Cash		-10.00K
YoY Change		-93.41%
FREE CASH FLOW
Cash From Operating Activities		-$600.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40386
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2076743
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6385 Old Shady Oak Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 250
	dei	Entity Address City Or Town EntityAddressCityOrTown	Eden Prairie
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55344
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	918-7189
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27987427	shares
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.0001
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	407000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2023Q4	ONMD	Yorkville Notes Payable Current YorkvilleNotesPayableCurrent		usd
CY2023Q4	us-gaap	Line Of Credit LineOfCredit		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue		usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q2	ONMD	Fair Value Adjustment Of Private Investment In Public Equity FairValueAdjustmentOfPrivateInvestmentInPublicEquity		usd
	ONMD	Fair Value Adjustment Of Private Investment In Public Equity FairValueAdjustmentOfPrivateInvestmentInPublicEquity		usd
CY2023Q2	ONMD	Change In Fair Value Of Note ChangeInFairValueOfNote		usd
	ONMD	Change In Fair Value Of Note ChangeInFairValueOfNote		usd
CY2023Q2	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1		usd
	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1		usd
CY2024Q2	ONMD	Vesting Of Restricted Stock Units Value VestingOfRestrictedStockUnitsValue		usd
	ONMD	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities		usd
	ONMD	Change In Fair Value Of Pipe Notes ChangeInFairValueOfPipeNotes		usd
	ONMD	Change In Fair Value Of Yorkville Note ChangeInFairValueOfYorkvilleNote		usd
	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	ONMD	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes		usd
	ONMD	Noncash Interest NoncashInterest		usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	ONMD	Business Combination Costs BusinessCombinationCosts		usd
	ONMD	Issuance Of Common Stock To Settle Deferred Underwriter Fee Payable IssuanceOfCommonStockToSettleDeferredUnderwriterFeePayable		usd
	ONMD	Consideration For Repurchase Of Common Stock Included In Accounts Payable And Accrued Expenses ConsiderationForRepurchaseOfCommonStockIncludedInAccountsPayableAndAccruedExpenses		usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
	dei	Entity Registrant Name EntityRegistrantName	ONEMEDNET CORPORATION
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	75000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	174000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	956000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	85000	usd
CY2024Q2	us-gaap	Assets Assets	1041000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6477000	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	519000	usd
CY2024Q2	ONMD	Loan Extensions Current LoanExtensionsCurrent	2992000	usd
CY2023Q4	ONMD	Loan Extensions Current LoanExtensionsCurrent	2992000	usd
CY2024Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1670000	usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1637000	usd
CY2024Q2	ONMD	Yorkville Notes Payable Current YorkvilleNotesPayableCurrent	2173000	usd
CY2024Q2	ONMD	Deferred Underwriter Fee Payable Current DeferredUnderwriterFeePayableCurrent	3323000	usd
CY2024Q2	us-gaap	Line Of Credit LineOfCredit	500000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20046000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13838000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	22000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	68000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	20228000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13906000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24050010	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23862265	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23572232	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23572232	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	78478000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	77996000	usd
CY2024Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	187745	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2024Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	529000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97138000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91440000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-19187000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-13442000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1041000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	464000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	227000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	173000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	476000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	356000	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	329000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	230000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	646000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	519000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	-102000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	-57000	usd
	us-gaap	Gross Profit GrossProfit	-170000	usd
	us-gaap	Gross Profit GrossProfit	-163000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1716000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	624000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3073000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1163000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	253000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	311000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	483000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	571000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	383000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	579000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	828000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1161000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	2352000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1514000	usd
	us-gaap	Operating Expenses OperatingExpenses	4384000	usd
	us-gaap	Operating Expenses OperatingExpenses	2895000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2454000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1571000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4554000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3058000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	41000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	83000	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1000	usd
CY2024Q2	ONMD	Fair Value Adjustment Of Private Investment In Public Equity FairValueAdjustmentOfPrivateInvestmentInPublicEquity	52000	usd
	ONMD	Fair Value Adjustment Of Private Investment In Public Equity FairValueAdjustmentOfPrivateInvestmentInPublicEquity	33000	usd
CY2024Q2	ONMD	Change In Fair Value Of Note ChangeInFairValueOfNote	-823000	usd
	ONMD	Change In Fair Value Of Note ChangeInFairValueOfNote	-823000	usd
CY2024Q2	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1	-160000	usd
	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1	-160000	usd
CY2024Q2	ONMD	Stock Warrant Expense StockWarrantExpense	33000	usd
CY2023Q2	ONMD	Stock Warrant Expense StockWarrantExpense	2165000	usd
	ONMD	Stock Warrant Expense StockWarrantExpense	33000	usd
	ONMD	Stock Warrant Expense StockWarrantExpense	4100000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-26359000	usd
CY2023Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	1935000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	368000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7843000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-31899000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-31899000	usd
CY2023Q2	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	2165000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	280000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-9601000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-39055000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-39055000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5698000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17444000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	240000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	648000	usd
	ONMD	Stock Warrant Expense StockWarrantExpense	33000	usd
	ONMD	Stock Warrant Expense StockWarrantExpense	4100000	usd
	ONMD	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	1000	usd
	ONMD	Change In Fair Value Of Pipe Notes ChangeInFairValueOfPipeNotes	33000	usd
	ONMD	Change In Fair Value Of Yorkville Note ChangeInFairValueOfYorkvilleNote	823000	usd
	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1	-160000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	15000	usd
	ONMD	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	10250000	usd
	ONMD	Noncash Interest NoncashInterest	67000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-77000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	107000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	8000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-17000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	950000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	279000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	265000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	278000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3053000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1966000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7000	usd
	ONMD	Proceeds From Issuance Of Shareholder Loans ProceedsFromIssuanceOfShareholderLoans	2000000	usd
	ONMD	Proceeds From Issuance Of Shareholder Loans ProceedsFromIssuanceOfShareholderLoans	604000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	100000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	500000	usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	30000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1350000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2100000	usd
	ONMD	Business Combination Costs BusinessCombinationCosts	690000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3720000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2014000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	660000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	41000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	47000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	271000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	707000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	312000	usd
	ONMD	Issuance Of Common Stock To Settle Deferred Underwriter Fee Payable IssuanceOfCommonStockToSettleDeferredUnderwriterFeePayable	242000	usd
	ONMD	Consideration For Repurchase Of Common Stock Included In Accounts Payable And Accrued Expenses ConsiderationForRepurchaseOfCommonStockIncludedInAccountsPayableAndAccruedExpenses	-529000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5700000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97100000	usd
CY2024Q2	us-gaap	Cash Cash	400000	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4500000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	50000	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.20
CY2024Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	50000	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.20
	ONMD	Stock Warrant Expense StockWarrantExpense	33000	usd
CY2024Q2	ONMD	Yorkville Notes Payable Current YorkvilleNotesPayableCurrent	2200000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2023Q4	us-gaap	Business Combination Cost Of Acquired Entity Equity Interests Issued And Issuable Fair Value Method BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod	the Company was obligated to compensate EF Hutton at a new share price equal to the difference in amount on such date. Due to the decrease in share value on the six-month anniversary, the Company was required to either pay to EF Hutton an additional $2.8 million or issue to EF Hutton an additional 3,175,000 shares of Common Stock.
CY2024Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	277778	shares
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	200000	usd
	us-gaap	Business Combination Cost Of Acquired Entity Equity Interests Issued And Issuable Fair Value Method BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod	the Company was obligated to pay to EF Hutton the true-up of either $2.8 million or 3,175,000 shares of Common Stock valued at $0.88 per share, plus the $0.5 million promissory note. Upon the occurrence of an event of default, the promissory note bears interest at a rate of 12.5% until such event of default is cured.
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-03-01
CY2024Q2	us-gaap	Interest Expense InterestExpense	15000	usd
	us-gaap	Interest Expense InterestExpense	25000	usd
CY2024Q2	ONMD	Stockholders Deficit Description StockholdersDeficitDescription	An Advance may not exceed the greater of (i) 100% of the average of the daily trading volume of the Common Stock on Nasdaq, during the five consecutive trading days immediately preceding the date of the Advance, and (ii) five hundred thousand (500,000) shares of Common Stock.
CY2024Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	500000	usd
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	500000	usd
CY2024Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	200000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14874777	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15102501	shares
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	103000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	280000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	240000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	648000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12181019	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12181019	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12181019	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12181019	shares
CY2024Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	4025000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1660000	usd
	us-gaap	Proceeds From Loans ProceedsFromLoans	400000	usd
CY2024Q2	us-gaap	Other Long Term Debt OtherLongTermDebt	100000	usd
CY2024Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.080	pure
	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2024Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	754000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	454000	usd
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1600000	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	38000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	11000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	2392000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	465000	usd
CY2024Q2	us-gaap	Share Price SharePrice	10.00
	us-gaap	Lease Cost LeaseCost	530	usd
CY2024Q2	us-gaap	Payments For Rent PaymentsForRent	2000	usd
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	2000	usd
	us-gaap	Payments For Rent PaymentsForRent	4000	usd
	us-gaap	Payments For Rent PaymentsForRent	4000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-049637-index-headers.html	Edgar Link	pending
0001493152-24-049637-index.html	Edgar Link	pending
0001493152-24-049637.txt	Edgar Link	pending
0001493152-24-049637-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
onmd-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
onmd-20240630_cal.xml	Edgar Link	unprocessable
onmd-20240630_def.xml	Edgar Link	unprocessable
onmd-20240630_lab.xml	Edgar Link	unprocessable
onmd-20240630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ONMD
OneMedNet Corp Stock $onmd

2024 Q2 Form 10-Q Financial Statement

#000149315224049637 Filed on December 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONMD OneMedNet Corp Stock $onmd

2024 Q2 Form 10-Q Financial Statement

#000149315224049637 Filed on December 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONMD
OneMedNet Corp Stock $onmd